Benralizumab is currently in clinical development for treating eosinophilic oesophagitis (EoE). EoE
is a condition in which the oesophagus (gullet) becomes inflamed as a result of an allergic reaction.
The inflammation is caused by a type of white blood cell called eosinophils. The oesophagus
transmits food from the mouth to the stomach, so the inflammation makes swallowing difficult as
the oesophagus becomes narrower than usual.
Benralizumab for treating eosinophilic oesophagitis in people aged 12-65 years
Benralizumab is currently in clinical development for treating eosinophilic oesophagitis (EoE). EoE is a condition in which the oesophagus (gullet) becomes inflamed as a result of an allergic reaction. The inflammation is caused by a type of white blood cell called eosinophils
Interventions:
Benralizumab (Fasenra; MEDI563)
Indications:
Eosinophilic oesophagitis
Therapeutic Areas:
Gastroenterology
Year:
2022